A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.
| Author | |
|---|---|
| Abstract |
:
The burden of type 2 diabetes mellitus is growing rapidly, particularly in the Asia-Pacific region. The aim of this international, large-scale, observational study was to investigate the efficacy and tolerability of the antidiabetic agent acarbose as add-on or monotherapy in a range of patients with type 2 diabetes, including those with cardiovascular morbidities. The majority of practices were included from high-burden regions (predominantly those in the Asia-Pacific region). |
| Year of Publication |
:
2013
|
| Journal |
:
Clinical drug investigation
|
| Volume |
:
33
|
| Issue |
:
4
|
| Number of Pages |
:
263-74
|
| ISSN Number |
:
1173-2563
|
| URL |
:
https://dx.doi.org/10.1007/s40261-013-0063-3
|
| DOI |
:
10.1007/s40261-013-0063-3
|
| Short Title |
:
Clin Drug Investig
|
| Download citation |
